Both in Biotechnology
Liminatus Pharma vs AIM ImmunoTech
Over the past year LIMN returned −95.3% and AIM returned −93.7%; their daily moves had a correlation of 0.05.
LIMN −95.3% AIM −93.7%Growth of $1, one year, split-adjusted
| Metric | LIMN | AIM |
|---|---|---|
| Price | $3.91 | $0.1735 |
| Market cap | $5.3M | $6.8M |
| Today | −8.43% | −5.91% |
| 1 month | −7.6% | −32.9% |
| 6 months | −55.8% | −68.5% |
| Year to date | −87.2% | −84.6% |
| 1 year | −94.6% | −93.5% |
| Revenue growth (YoY) | — | +4.0% |
| Gross margin | — | 80.8% |
| Net margin | — | −26876.9% |
| P/E (TTM) | — | — |
| Price / sales | — | 71.6× |
| Net cash | — | $6.3M |
| Dividend yield | — | — |
| Volatility (60d) | 1,154.9% | 72.3% |
| Short % of float | 0.2% | 10.1% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).